Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Effect of Melatonin on Reducing the Frequency and Severity of Migraine Attacks: A Double-Blind, Randomized Clinical Trial Publisher Pubmed



Mehramiri A1 ; Shalilahmadi D1 ; Mohamadianinejad SE2 ; Kouti L3 ; Hosseinpour Y1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Neurology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
  2. 2. Department of Neurology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Clinical Pharmacy, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Source: Iranian Journal of Medical Sciences Published:2024


Abstract

Background: There is no definite recommendation for melatonin supplementation in episodic migraine. This study aimed to evaluate the effect of melatonin on reducing the frequency and severity of migraine attacks. Methods: This randomized, double-blind clinical trial was conducted at Golestan Hospital of Ahvaz, Iran, in 2021. A total of 60 patients with episodic migraine were randomly assigned into 2 groups of receiving 3 mg melatonin (intervention group; n=30) or the same dose of placebo (control group; n=30) along with baseline therapy (propranolol 20 mg, BID) for two months. The attack frequency, attack duration, attack severity (based on VAS), the number of analgesic intakes, drug complications, Migraine Disability Assessment score (MIDAS), and Pittsburgh sleep quality index (PSQI) were evaluated at baseline and in the first, second, third, and fourth months of follow-up. The independent t test, chi-square, and analysis of variance (ANOVA) with repeated measures were used to compare variables between the two groups. Results: In both groups, the frequency, duration, and severity of attacks, taking analgesics, MIDAS, and PSQI scores during follow-up decreased significantly (P<0.001). After treatment, the mean frequency (P=0.032) and duration of attacks (P=0.001), taking analgesic (P<0.001), and MIDAS (P<0.001) and PSQI scores (P<0.001) in the melatonin group were lower than placebo. Only the attack severity was not significantly different between the two groups (P=0.126). Side effects were observed in two patients (6.7%) in the melatonin group and one patient (3.3%) in the placebo group (P>0.999). Conclusion: Our study shows that melatonin was more efficacious than the placebo in the reduction of frequency and duration of migraine attacks. It was equally safe as the placebo and might be effective in the preventive treatment of episodic migraine in adults. © Iranian Journal of Medical Sciences.
Related Docs
View other Related Docs
1. Serum Melatonin Levels and in a Sample of Iranian Patients With Migraine, Scientific Reports (2024)
2. Debate: Differences and Similarities Between Tension-Type Headache and Migraine, Journal of Headache and Pain (2023)
3. Glia Signaling and Brain Microenvironment in Migraine, Molecular Neurobiology (2023)
4. Preventive Medications in Pediatric Migraine: A Network Meta-Analysis, JAMA Network Open (2024)
5. Effectiveness of Dry Needling for Improving Pain and Disability in Adults With Tension-Type, Cervicogenic, or Migraine Headaches: Protocol for a Systematic Review, Chiropractic and Manual Therapies (2019)
6. The Association Between Dietary Tryptophan Intake and Migraine, Neurological Sciences (2019)
7. Effect of Melatonin Supplementation on Sleep Quality: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Journal of Neurology (2022)
8. Assessment of Sleep Patterns in Migraine Sufferers Using the Epworth Sleepiness Scale, Journal of Headache and Pain (2025)
Experts (# of related papers)
View all Related Experts
Mansoureh Togha (6)
Khadijeh Mirzaei (2)
Other Related Docs
9. Evaluation of Serum Levels of Transient Receptor Potential Cation Channel Subfamily V Member 1, Vasoactive Intestinal Polypeptide, and Pituitary Adenylate Cyclase-Activating Polypeptide in Chronic and Episodic Migraine: The Possible Role in Migraine Transformation, Frontiers in Neurology (2021)
10. Migraine Management: Non-Pharmacological Points for Patients and Health Care Professionals, Open Medicine (Poland) (2022)
11. The Association Between Dietary Glycemic Index and Disease Severity Among the Women With Episodic Migraine, Nutritional Neuroscience (2024)
12. Migraine - a Borderland Disease to Epilepsy: Near It But Not of It, Journal of Headache and Pain (2024)
13. Resistant and Refractory Migraine – Two Different Entities With Different Comorbidities? Results From the Refine Study, Journal of Headache and Pain (2024)
14. A Comparative Study on Prophylactic Efficacy of Cinnarizine and Amitriptyline in Childhood Migraine: A Randomized Double-Blind Clinical Trial, Cephalalgia (2024)
15. Preventive Effect of Greater Occipital Nerve Block on Patients With Episodic Migraine: A Randomized Double‐Blind Placebo‐Controlled Clinical Trial, Cephalalgia (2022)
16. Erenumab Efficacy in Migraine Headache Prophylaxis: A Systematic Review, International Immunopharmacology (2023)
17. Insights From Triggers and Prodromal Symptoms on How Migraine Attacks Start: The Threshold Hypothesis, Cephalalgia (2024)
18. The Sense of Stopping Migraine Prophylaxis, Journal of Headache and Pain (2023)
19. The Effectiveness of Agomelatine on Headache Severity and Frequency in Episodic Migraine Without Aura; a Parallel Randomized Controlled Trial Study, BMC Neurology (2024)
20. Intravenous Caffeine Citrate Vs. Magnesium Sulfate for Reducing Pain in Patients With Acute Migraine Headache; a Prospective Quasi-Experimental Study, Korean Journal of Pain (2017)
21. The Association Between Adherence to Alternative Healthy Diet Index (Ahei) and Severity, Disability, Duration, and Frequency of Migraine Headache Among Women: A Cross-Sectional Study, Nutrition Journal (2023)
22. The Relationship Between Dietary Nutrients Patterns and Intensity and Duration of Migraine Headaches, British Journal of Nutrition (2023)